Ground News

News from ophthalmologytimes.com

Your destination for news from ophthalmologytimes.com. See how ophthalmologytimes.com’s media bias impacts the breaking news stories of today.

Ground News has come across 335 headlines reported on by ophthalmologytimes.com during the past 3 months.

We’ve assigned a media bias rating of unknown to ophthalmologytimes.com. You can read more about our methodology here.

ophthalmologytimes.com’s aggregated factuality score is Unknown. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about ophthalmologytimes.com

Where is ophthalmologytimes.com located?ophthalmologytimes.com's Website

Media Bias Ratings

Do you diasgree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top ophthalmologytimes.com News

Health

Study identifies potential way to slow or block progression of age-related macular degeneration

75% Center coverage: 4 sources

A new study from Washington University School of Medicine in St. Louis identifies a possible way to slow or block progression of age-related macular degeneration, a leading cause of blindness in people over age 50.See the Story

Startup That Makes Robots For Cataract Surgery Raises $125 Million In Second-Largest Fundraise For A Surgical Robotics Firm

100% Center coverage: 2 sources

Millions of people get cataract surgery every year. What if a robot could do it better than humans?See the Story

Opus Genetics Reports Positive Phase 3 Results for Phentolamine Ophthalmic Solution 0.75%

Phentolamine Ophthalmic Solution 0.75% is a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, administered as an eye drop for the treatment of presbyopia.See the Story

Stuart Reports Initial Outcomes From Trial of Ophthalmic Solution for DED

Stuart Therapeutics has reported initial findings from its Phase III trial of ST-100 ophthalmic solution for dry eye disease (DED).The post Stuart reports initial outcomes from trial of ophthalmic solution for DED appeared first on Clinical Trials Arena.See the Story

Valorum Biologics to Commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada

FYB203 has been approved by the US FDA and UK Medicines and Healthcare products Regulatory Agency for the treatment of neovascular age-related macular degeneration (nAMD), diabetic macular edema, macular edema following retinal vein occlusion, and visual impairment due to myopic choroidal neovascularization.United States · United States See the Story

Qlaris Bio to present new data on QLS-111 at the 2025 World Glaucoma Congress

Qlaris Bio to showcase promising data on QLS-111, a novel glaucoma treatment, at the 2025 World Glaucoma Congress, highlighting its efficacy and safety.Read Article

Aldeyra Therapeutics receives Special Protocol Assessment Agreement Letter from FDA for ADX-2191

ADX-2191 is an investigational drug candidate from Aldeyra, for the treatment of primary vitreoretinal lymphoma (PVRL), a rare and potentially fatal cancer currently with no current FDA-approved therapyCancer · United States Read Article

36-month results from phase 1/2a clinical study of RG6501 released

New findings reveal RG6501 cell therapy shows promising long-term visual improvements for geographic atrophy patients Read Article

Perfuse Therapeutics shares positive results from Phase 2 clinical trials of PER-001

Perfuse Therapeutics reveals promising Phase 2 trial results for PER-001, a potential treatment for glaucoma and diabetic retinopathy.See the Story

tPA: A (new) tool in the uveitis armamentarium for patient care

Intracameral tPA can treat fibrinous clots in severe anterior uveitis.Santiago · Santiago See the Story

Breye Therapeutics Reports Completion of Phase 1b for Oral NPDR Therapy

Danegaptide is an oral therapy for early treatment of non-proliferative diabetic retinopathy (NPDR) and associated edema.See the Story

News from ophthalmologytimes.com

News from ophthalmologytimes.com

Information about ophthalmologytimes.com

Media Bias Ratings

Factuality

Ownership

Top ophthalmologytimes.com News

Study identifies potential way to slow or block progression of age-related macular degeneration

Startup That Makes Robots For Cataract Surgery Raises $125 Million In Second-Largest Fundraise For A Surgical Robotics Firm

Opus Genetics Reports Positive Phase 3 Results for Phentolamine Ophthalmic Solution 0.75%

Stuart Reports Initial Outcomes From Trial of Ophthalmic Solution for DED

Valorum Biologics to Commercialize Formycon’s Eylea Biosimilar FYB203 in US and Canada

Qlaris Bio to present new data on QLS-111 at the 2025 World Glaucoma Congress

Aldeyra Therapeutics receives Special Protocol Assessment Agreement Letter from FDA for ADX-2191

36-month results from phase 1/2a clinical study of RG6501 released

Perfuse Therapeutics shares positive results from Phase 2 clinical trials of PER-001

tPA: A (new) tool in the uveitis armamentarium for patient care

Breye Therapeutics Reports Completion of Phase 1b for Oral NPDR Therapy

Similar News Topics

Topics Most Covered by ophthalmologytimes.com

Sources Covering Similar Topics

Breaking News Topics Related to ophthalmologytimes.com